MS-DRG · FY 2026 v43.0

MS-DRG 18 – Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies

A Medical DRG in Pre-MDC (Pre-MDC). Its FY 2026 relative weight is 43.1828 with a geometric mean length of stay of 12.4 days.

Medical DRG – assigned by principal diagnosis✓ Official CMS v43.0 dataset
43.1828
Relative Weight
12.4
Geometric Mean LOS (days)
14.7
Arithmetic Mean LOS (days)
40
Procedure Codes
How a case is assigned to DRG 18

The grouper first assigns the case to Pre-MDC from the principal diagnosis and finds no qualifying operating-room procedure (this is a Medical DRG; ICD-10-PCS codes do not drive assignment here).

ICD-10-CM

Principal Diagnosis Codes

Diagnosis codes do not drive assignment for this DRG. Cases group here from the ICD-10-PCS procedure list.
ICD-10-PCS

Procedure Codes 40 codes · 10 categories

40 of 40 shown
XHR0 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR0XGA Replacement of Head and Neck Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR1 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR1XGA Replacement of Chest Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR2 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR2XGA Replacement of Abdomen Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR3 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR3XGA Replacement of Back Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR4 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR4XGA Replacement of Right Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR5 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR5XGA Replacement of Left Upper Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR6 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR6XGA Replacement of Right Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XHR7 New Technology, Skin, Subcutaneous Tissue, Fascia and Breast, Replacement1 code
  • XHR7XGA Replacement of Left Lower Extremity Skin with Prademagene Zamikeracel, Genetically Engineered Autologous Cell Therapy, External Approach, New Technology Group 10
XW03 New Technology, Anatomical Regions, Introduction16 codes
  • XW03368 Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW03378 Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8
  • XW0338A Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033A7 Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10
  • XW033FB Introduction of Valoctocogene Roxaparvovec-rvox into Peripheral Vein, Percutaneous Approach, New Technology Group 11
  • XW033G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033J7 Introduction of Tisagenlecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033L7 Introduction of Lifileucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7
  • XW033RB Introduction of Letetresgene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 11
XW04 New Technology, Anatomical Regions, Introduction16 codes
  • XW04368 Introduction of Afamitresgene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW04378 Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
  • XW0438A Introduction of Obecabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043A7 Introduction of Ciltacabtagene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043BA Introduction of Orca-T Allogeneic T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043C7 Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043FA Introduction of Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043FB Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043G7 Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043H7 Introduction of Axicabtagene Ciloleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043J7 Introduction of Tisagenlecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043K7 Introduction of Idecabtagene Vicleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043L7 Introduction of Lifileucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043M7 Introduction of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043N7 Introduction of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 7
  • XW043RB Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11

Frequently Asked Questions

What is MS-DRG 18?

MS-DRG 18 (Chimeric Antigen Receptor (CAR) T-Cell and Other Immunotherapies) is a medical DRG in Pre-MDC (Pre-MDC). Its FY 2026 relative weight is 43.1828 with a geometric mean length of stay of 12.4 days.

What is the relative weight of DRG 18?

The FY 2026 relative weight of this DRG is 43.1828, meaning reimbursement of roughly 43.18 times the average Medicare inpatient case. Multiply by a hospital's blended base rate for the approximate payment.

← PreviousDRG 17 – Autologous Bone Marrow Transplant without CC/MCC
Source: CMS ICD-10 MS-DRG v43.0 Definitions Manual and the FY 2026 IPPS Final Rule (Table 5), effective October 1, 2025 through September 30, 2026. We publish the DRG assignments as CMS defines them and add the navigation, search, and code links.